Oleoylethanolamide (Synonyms: N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide)

Name: Oleoylethanolamide
Brand: MedChemExpress
SKU: HY-107542
Rating: 4.5 (1 reviews)

Cat. No.: HY-107542 Purity: 99.94%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

For research use only. We do not sell to patients.

Oleoylethanolamide Chemical Structure

CAS No. : 111-58-0

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 90	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 320	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 480	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Oleoylethanolamide:

Oleoylethanolamide-d₄ Get quote
Oleoylethanolamide-d₂ Get quote

1 Publications Citing Use of MCE Oleoylethanolamide

•J Agric Food Chem. 2024 Sep 13. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

IC₅₀ & Target^[1]

Human Endogenous Metabolite

PPAR-α

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	35.4 μg/mL Compound: 4c	Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
HEK293	EC₅₀	2.2 μM Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay	[PMID: 27825553]
HEK293	EC₅₀	2.2 μM Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay	[PMID: 28408218]
HEK293	EC₅₀	2.2 μM Compound: OEA	Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins	[PMID: 23357035]
HEK293	EC₅₀	2200 nM Compound: OEA	Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine	[PMID: 23374864]
HeLa	EC₅₀	0.12 μM Compound: OEA	Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
HeLa	EC₅₀	1.1 μM Compound: OEA	Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay	[PMID: 27622746]
MCF7	EC₅₀	152 nM Compound: OEA	Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay	[PMID: 26226490]
MCF7	EC₅₀	152 nM Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay	[PMID: 24936232]
MCF7	EC₅₀	185 nM Compound: OEA	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay	[PMID: 24936232]
MCF7	GI₅₀	25.9 μg/mL Compound: 4c	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
NCI/ADR-RES	GI₅₀	9.1 μg/mL Compound: 4c	Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
NCI-H460	GI₅₀	36.5 μg/mL Compound: 4c	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
OVCAR-3	GI₅₀	35.4 μg/mL Compound: 4c	Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
PC-3	GI₅₀	16.9 μg/mL Compound: 4c	Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]
RBL-2H3	IC₅₀	> 50 μM Compound: 10	Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2 Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2	[PMID: 31618024]
SK-OV-3	IC₅₀	24 μM Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC	[PMID: 20085856]
SK-OV-3	IC₅₀	28 μM Compound: N-oleylethanolamine	Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay	[PMID: 20085856]
U-251	GI₅₀	27.3 μg/mL Compound: 4c	Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 25510639]

In Vitro

Oleoylethanolamide (OEA), an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oleoylethanolamide suppresses TGF-β1 induced hepatic stellate cells (HSCs) activation in vitro via PPAR-α. To assess the impact of Oleoylethanolamide on HSCs activation, the expression levels of α-SMA and Col1a in TGF-β1-stimulated HSCs are examined by qPCR. The mRNA levels of α-SMA and Col1a are markedly induced in the group of CFSC cells with TGF-β1 (5 ng/mL) stimulation for 48h, while the mRNA levels are suppressed when treated with Oleoylethanolamide in a dose-dependent manner. Immunofluorescence and western blot results show that Oleoylethanolamide treatment dose-dependently inhibits the protein expression of α-SMA, the marker of HSC activation. The inhibitory effects of Oleoylethanolamide on HSCs activation are completely blocked by PPAR-α antagonist MK886 (10 μM). Moreover, the mRNA and protein expression levels of PPAR-α are down-regulated with TGF-β1 stimulation, while Oleoylethanolamide treatment restores these changes in dose-dependent manner. In addition, the phosphorylation of Smad 2/3 is upregulated in the presence of TGF-β1 stimulation, consistent with the observed effects on HSC activation, while Oleoylethanolamide (10 μM) reduces the phosphorylation of Smad2/3 in CFSC simulated with TGF-β1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Oleoylethanolamide (OEA) can significantly suppress the pro-fibrotic cytokine TGF-β1 negatively regulate genes in the TGF-β1 signaling pathway (α-SMA, collagen 1a, and collagen 3a) in mice models of hepatic fibrosis. Treatment with Oleoylethanolamide (5 mg/kg/day, intraperitoneal injection, i.p.) significantly attenuates the progress of liver fibrosis in both two experimental animal models by blocking the activation of hepatic stellate cells (HSCs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

325.53

Formula

C₂₀H₃₉NO₂

CAS No.

111-58-0

Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCC/C=C\CCCCCCCC(NCCO)=O

Structure Classification

Others

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 20.83 mg/mL (63.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0719 mL	15.3596 mL	30.7191 mL
5 mM	0.6144 mL	3.0719 mL	6.1438 mL
10 mM	0.3072 mL	1.5360 mL	3.0719 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (272 KB) SDS (252 KB)

COA (238 KB) HNMR (291 KB) LCMS (258 KB)

Handling Instructions (2659 KB)

References

[1]. Chen L, et al. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget. 2015 Dec 15;6(40):42530-40 [Content Brief]

Cell Assay ^[1]	CFSC, HSC cell lines are first obtained from cirrhotic rat liver, and have a similar phenotype to that of early passage primary HSCs. CFSC cells are cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cells are cultured in 6-well culture plates under 37°C and 5% CO₂ in an incubator. The medium is replaced every two days, and the cells are harvested and diluted at a ratio of 1:3 twice a week. In experiments, HSCs are pretreated with the experimental concentration of Oleoylethanolamide (30 μM, 10 μM, 3 μM) before stimulation with 5 ng/mL TGF-β1. mRNA expression levels of α-SMA (A) and Col1a (B) are analyzed by real-time PCR^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] The Sv/129 mice and PPAR-α knockout mice are maintained in a room with controlled temperature (21-23°C), humidity (55-60%) and lighting (12 h light/dark cycles) and given water ad libitum. Mice are randomly divided for methionine choline-deficient (MCD) and thioacetamide (TAA) experiments. In the MCD-diet feeding experiment, wild-type Sv/129 mice and PPAR-α knockout mice are each divided into three groups (n=8 /group): (i) control group receive normal diet; (ii) fed with MCD diet and injected with the vehicle (5% Tween-80+5% PEG400+90% saline, 5 mL/kg/day, 8 weeks, intraperitoneal injection, i.p.); (iii) fed with MCD diet along with Oleoylethanolamide administration (5 mg/kg/day; 8 weeks, i.p.). In another set of experiment, all the wild-type mice and PPAR-α knockout mice are given standard chow diet, and are randomly separated into three groups: the control group is not administrated TAA or Oleoylethanolamide but is injected with the saline; the TAA group is injected with TAA (160 mg/kg, three times per week, 6 weeks, dissolved in saline, i.p.) plus the corresponding vehicle; the Oleoylethanolamide group is both injected with TAA and Oleoylethanolamide (5 mg/kg/day; 6 weeks, i.p.)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Chen L, et al. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget. 2015 Dec 15;6(40):42530-40 [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0719 mL	15.3596 mL	30.7191 mL	76.7978 mL
	5 mM	0.6144 mL	3.0719 mL	6.1438 mL	15.3596 mL
	10 mM	0.3072 mL	1.5360 mL	3.0719 mL	7.6798 mL
	15 mM	0.2048 mL	1.0240 mL	2.0479 mL	5.1199 mL
	20 mM	0.1536 mL	0.7680 mL	1.5360 mL	3.8399 mL
	25 mM	0.1229 mL	0.6144 mL	1.2288 mL	3.0719 mL
	30 mM	0.1024 mL	0.5120 mL	1.0240 mL	2.5599 mL
	40 mM	0.0768 mL	0.3840 mL	0.7680 mL	1.9199 mL
	50 mM	0.0614 mL	0.3072 mL	0.6144 mL	1.5360 mL
	60 mM	0.0512 mL	0.2560 mL	0.5120 mL	1.2800 mL

Oleoylethanolamide Related Classifications

Metabolic Disease Cardiovascular Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Oleoylethanolamide111-58-0N-Oleoylethanolamide Oleamide MEA Oleic acid monoethanolamideEndogenous MetabolitePPARPeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Oleoylethanolamide (Synonyms: N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide)

Customer Review

Other Forms of Oleoylethanolamide:

Oleoylethanolamide Related Antibodies

1 Publications Citing Use of MCE Oleoylethanolamide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Oleoylethanolamide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Oleoylethanolamide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report